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Epidemics of dengue, Zika, and other arboviral diseases are increasing in frequency and severity. Current efforts to rapidly iden-
tify and manage these epidemics are limited by the short diagnostic window in acute infection, the extensive serologic cross-reac-
tivity among flaviviruses, and the lack of point-of-care diagnostic tools to detect these viral species in primary care settings. The 
Partnership for Dengue Control organized a workshop to review the current landscape of Flavivirus diagnostic tools, identified cur-
rent gaps, and developed strategies to accelerate the adoption of promising novel technologies into national programs. The rate-lim-
iting step to bringing new diagnostic tools to the market is access to reference materials and well-characterized clinical samples to 
facilitate performance evaluation. We suggest the creation of an international laboratory-response consortium for flaviviruses with a 
decentralized biobank of well-characterized samples to facilitate assay validation. Access to proficiency panels are needed to ensure 
quality control, in additional to in-country capacity building.
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Zika virus (ZIKV) and the dengue viruses (DENVs) are arthro-
pod-borne viruses (arboviruses) of the Flaviviridae family that 
cocirculate in tropics and subtropics along with other arbovi-
ruses that share the same Aedes species mosquito vectors [1]. 
Several factors, including viral evolution, redistribution of vec-
tors, ineffective vector control strategies, population growth, 
urbanization, and globalization have contributed to the global 
spread of DENV, ZIKV, and other arboviruses [2].
Up to 400 million DENV infections are estimated to occur 
every year [3], and infection with any of the 4 DENV serotypes 
(DENV1–4) can cause severe and sometimes fatal disease. The 
geographical expansion of dengue is increasingly associated 
with more-severe disease outcomes [2, 4]. ZIKV is following the 
global spread of DENV [2]. ZIKV infections were first thought 
to only cause sporadic and mild disease in parts of Africa and 
Asia [5]. A major Zika outbreak with a high attack rate occurred 
for the first time in 2007. During a subsequent outbreak in the 
Pacific (French Polynesia) in 2013, ZIKV was linked to severe 
neurological disease in humans [6]. The recent explosive 
outbreak in the Americas unmasked the association between 
prenatal ZIKV infections and severe birth defects [2, 6].
No specific therapeutic options exist for DENV or ZIKV 
infections. For DENV, a vaccine was recently licensed but has 
not yet been implemented widely in any of the affected countries 
[7]; for ZIKV, at least 45 vaccine candidates are now in devel-
opment, but a licensed vaccine will not be available for years to 
come [8]. There is an urgent need for highly specific diagnostic 
assays that can identify and discriminate between cocirculating 
DENV and ZIKV for efficient case management, surveillance, 
control, and vaccine trials. In May 2017, the Partnership for 
Dengue Control (PDC) [9] organized a workshop with approx-
imately 80 key stakeholders and thought leaders to address crit-
ical issues related to the diagnosis and surveillance of ZIKV and 
DENV. The workshop was organized around 3 questions: What 
is the status of Zika and dengue diagnostic tools? What tech-
nological innovations might be available in the near, interme-
diate, and long-term future? and What is needed to make these 
technologies readily available where they are most needed? The 
following is a summary of key outcomes that emerged from the 
meeting.
WHAT IS THE STATUS OF ZIKA AND DENGUE 
DIAGNOSTIC TOOLS?
Individuals infected with DENV and ZIKV may be asympto-
matic or display a similar constellation of initial clinical symp-
toms [10]. Hence, virus-specific assays are required for accurate 
diagnosis. Since the first isolation of DENV during World War 
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II [11, 12], a number of diagnostic methods commonly used for 
viral detection, such as viral isolation, plaque reduction neu-
tralization test (PRNT), the immunoglobulin M (IgM) enzyme-
linked immunosorbent assay (ELISA), and, in the 1990s, reverse 
transcription–polymerase chain reaction (RT-PCR) [13] were 
developed for DENV (Figure  1) and other medically relevant 
flaviviruses.
Assays to detect DENV and ZIKV can be divided into 2 main 
categories: (1) assays to detect the pathogen (viral isolation, viral 
nucleic acid testing, or viral antigen detection); and (2) assays 
to detect exposure to the pathogen (detection of virus-specific 
antibodies such as IgM, immunoglobulin G, and immunoglob-
ulin A). Assay selection depends both on the timing of sample 
collection and the purpose of testing (Figure  2). The viremic 
period of flaviviral infections is transient and short-lived; the 
duration of viral shedding and the presence of ZIKV RNA can 
be variable across sample types (eg, serum, whole blood, urine, 
saliva, and amniotic fluid) [6, 14] and different hosts (eg, preg-
nant women and other adults) [15]. A negative viral isolation 
and/or nucleic acid test result does not exclude the presence of 
a current infection.
In the convalescent phase of infection, serologic meth-
ods are preferred, although paired acute and convalescent 
phase samples are required to distinguish current from past 
infections [16]. The major challenge of ZIKV and DENV 
diagnosis by serologic analysis is the extensive cross-reac-
tivity of antibody responses resulting from prior flaviviral 
infections and/or vaccination [17–19]. Figure 3 details the 
applications, advantages, and limitations of the different 
types of assays available for the detection of DENV and 
ZIKV infections.
LANDSCAPE OVERVIEW AND EXISTING GAPS
Both in-house laboratory-developed tests (LDTs) and com-
mercial kits are available to detect ZIKV and DENV infections 
(Figure 4). Most of the available technologies require laboratory 
facilities with appropriate diagnostic competence (Figure  4); 
point-of-care assays remain limited. Zika commercial kits in-
clude nucleic acid tests and serologic assays. The current ZIKV 
nucleic acid tests have not yet gone through much rigorous 
evaluations [20], and the evidence is even scarcer for serologic 
assays. Antigen detection assays for the diagnosis of ZIKV 
infections are currently not available on the market.
Performance of commercial dengue diagnostic tools has 
improved over the last decade. These include 2 Food and Drug 
Administration (FDA)–approved assays (1 RT-PCR and 1 IgM-
capture ELISA). Additionally, there are several rapid lateral flow 
assays (RDTs) for the detection of DENV NS1 antigen, DENV-
specific IgM antibodies, or both (Figure 4), none of which are 
FDA approved. RDTs hold promise as future point-of-care 
applications; however, the clinical performance of these assays 
has been highly variable [21].
While dengue serologic assays have been clinically validated, 
their specificity has decreased by cross-reactivity in the con-
text of the recent cocirculation of ZIKV [22]. To date, very few 
dengue and Zika diagnostic assays have been adequately and 
independently evaluated using clinical specimens from both 
ZIKV-infected and DENV-infected populations. Diagnostic 
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Figure 1. Historical time line of the development of dengue diagnostic tools, 1940s–1990s. Dengue virus (DENV) was first isolated in the early 1940s by groups led by 
Albert Sabin and Susumu Hotta. A number of viral isolation, serological, and molecular methods have since been developed. IF, immunofluorescence; ELISA, enzyme-linked 
immunosorbent assay; IgM, immunoglobulin M; RT-PCR, reverse transcription–polymerase chain reaction.
assays that can accurately detect and distinguish cocirculating 
flaviviral infections and predict severe disease outcomes at or 
near the point-of-care are urgently needed.
WHAT TECHNOLOGICAL INNOVATIONS MIGHT BE 
AVAILABLE IN THE NEAR, INTERMEDIATE, AND 
LONG-TERM FUTURE?
Different companies and research groups were invited to pre-
sent technologies to detect DENV and ZIKV. In the following, 
we discuss the technologies in the pipeline (Figure 4) and their 
potential to change the paradigm of flaviviral diagnosis.
Pipeline Assays to Detect the Pathogen
Nucleic-Acid Testing
Simpler and faster alternatives to traditional RT-PCR meth-
ods have the potential to be used at or near the point-of-care. 
These include cartridge-based sample-in-answer-out multiplex 
real-time RT-PCR assays that can simultaneously detect ZIKV, 
DENV1–4, other arboviruses (eg, chikungunya virus, an alpha-
virus), and other viruses (3-plex to 6-plex combinations) from 
a single specimen in <2 hours. Arboviral assays are being de-
veloped for use on existing industry platforms that were previ-
ously validated and implemented for other molecular tests. This 
strategy illustrates the usefulness of open-platform systems that 
can easily incorporate newly developed molecular amplification 
methods to suit an emergent medical need, such as the ZIKV 
epidemic. Another advantage of these systems is the ability to 
transmit data wirelessly and monitor the results remotely. The 
disadvantages are that these platforms are costly and that some 
require technical expertise and laboratory infrastructure that 
are not widely available.
The development of more-portable molecular platforms 
linked to faster isothermal amplification methods independent 
of thermal cycling, such as recombinase polymerase amplifica-
tion [23] and loop-mediated isothermal amplification, are also 
underway for singleplex and multiplex detection of ZIKV and 
other arboviruses. In prototype formats, results can be achieved 
in <1 hour, and assays can potentially be applied to settings 
without electricity or highly trained users. Proof-of-principle 
studies exist [23–30], but further simplification of sample prep-
aration and more-robust clinical performance evaluation will 
be required. Innovative technologies, such as clustered regu-
larly interspaced short palindromic repeats  (CRISPR)–based 
RNA sensing, robotics, microfluidics, smartphones, and 3D 
printers, are being used to develop these assays. Other nucleic 
acid testing innovations include the use of paper-based strips 
for multiplex detection of ZIKV, DENV, and chikungunya virus 
end point RT-PCR products [31].
Antigen Detection Assays
High-affinity monoclonal antibodies that recognize specific 
epitopes on ZIKV antigens are required to develop antigen 
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Figure 2. Schematic representation of the typical kinetics of flaviviral infections (adapted from Peeling et al 2010 with permission). As for most arboviral infections, viremia 
(red line) normally precedes the onset of clinical symptoms (0) and lasts for a few days after symptom onset. A, During the acute phase, flaviviral infections are best detected 
by viral isolation, nucleic acid amplification tests (NATs), and antigen detection assays (eg, the dengue virus NS1 assay). B, During the course of infection, viral-specific im-
munoglobulin M (IgM; blue line) and immunoglobulin G (IgG; green line) antibodies are produced and can be used to detect exposure to the pathogen. Current infections can 
be diagnosed by the detection of IgM and IgG antibodies in paired acute and convalescent phase samples (ie, detection of seroconversion of a ≥4-fold rise in the IgG or total 
antibody titer). IgM antibodies can persist for several months, and IgG antibodies are known to persist for several years. C, Combination assays that detect both antigen and 
antibodies are applicable throughout the entire spectrum of disease. ELISA, enzyme-linked immunosorbent assay; RDT, rapid diagnostic test.
detection assays and are either in development or were devel-
oped for NS1 [32, 33], including the development of RDTs [34].
Pipeline Assays to Detect Past Exposure
Given our understanding of the cross-reactivity of current an-
tibody detection methods for flaviviruses, there is a lack of reli-
able reference diagnostic tools against which to compare newly 
developed specific serologic assays. Detection of virus-specific 
neutralizing antibodies by PRNT can be useful to discriminate 
viral species and serotypes in primary infections. However, the 
specificity of PRNT in sequential DENV infections or sequen-
tial DENV and ZIKV infections and at early time points after 
infection is limited [32, 35, 36]. Interestingly, little cross-neu-
tralization is detected in samples collected during the late 
convalescent phase (ie, >2 months) after DENV and ZIKV in-
fection [37]. These observations highlight the importance of the 
timing of sample collection and the history of exposure to past 
infections to inform the serodiagnosis of flaviviral infections. 
It is critical to evaluate multiple flaviviruses simultaneously in 
neutralization assays to interpret the results appropriately.
Strongly neutralizing human monoclonal antibodies target 
quaternary structure epitopes that typically bind across envelope 
proteins displayed on the surface of the viral particles [38–40]. 
Epitopes with high sequence homology among serotypes and 
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result: probable. Useful for surveillance.
Detection of  past infection. Classification of  primary or
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Can be used as ELISA (high throughput) or as RDT at or
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Limited specificity due to high cross-reactivity among
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Limited sensitivity during acute phase of  infection;
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Confirmatory results can only be obtained after a second
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Detection of  past infection. Identification of  viral species and
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Higher specificity than IgM/IgG assays;
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allows the detection and isolation of  living virus.
Highly accurate if  performed correctle; faster and less
laborious than viral isolation; multiplex and near point-of-care
testing possible.
Diagnostic window of  DENV NS1 up to day 8 post-onset of
DENV infection with less sensitivity; ELISA (high throughput)
or RDT; can be used at or near the point-of-care; easy to
perform; less expensive.
Less accurate than viral isolation and NAT, requires acute
sample, variable results according to serotype and immune
status. No antigen antigen detection assay availbale for ZIKV
at present.
Less accurate than viral isolation and NAT during acute phase. Variation among laboratories. No assays availbale for ZIKV at present.
Entire temporal spectrum following infection (applicable in acute and convalescent samples); RDT; can be used at or near the point of  care;
easy to perform; less expensive; can use whole blood.
Mainly laboratory based; requires acute sample; complex; requires
power supply; expensive; potential false positives.
Lab-based; requires acute sample; takes more than one week
to complete; expensive; laborious and impractical in point-of-
care and resource-limited settings.
Figure 3. Applications, advantages, and limitations of the main diagnostic tests in use for the detection of flaviviral infections. A, Assays to detect the pathogen directly: 
viral isolation, nucleic acid amplification tests (NATs), and antigen detection assays. B, Assays to detect exposure to infection. C, Combination assays to detect both the 
pathogen and exposure to infection. aRNA copy number is not an accurate measure of infectious virus (viral RNA can persist for longer periods than infectious virus). DENV, 
dengue virus; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; IgM, immunoglobulin M; RDT, rapid diagnostic test; ZIKV, Zika virus.
viral species can trigger cross-reactive antibody responses, 
whereas unique epitopes can lead to type-specific antibody 
responses. This information is being used to rationally design 
ZIKV and DENV envelope and NS1 recombinant antigens for 
specific serologic assays.
Isolated human ZIKV type-specific anti-NS1 monoclonal 
antibodies were used to identify type-specific recognition sites 
on ZIKV NS1 protein by antibody competition assays [32]. One 
of these antibodies was adapted to a competition-based ELISA, 
in which serum antibodies are measured for their ability to block 
the binding of a ZIKV NS1-specific monoclonal antibody to sol-
id-phase ZIKV NS1 [41]. This approach, named “ZIKV NS1 
blockade-of-binding (BOB) ELISA,” was shown to be more spe-
cific than traditional ELISAs. Clinical validation in large multi-
center cohorts of patients stratified by exposure to DENV and 
ZIKV infection, immune status, and timing of sample collection 
confirmed the high specificity and sensitivity of the assay [41]. 
The ZIKV NS1 blockade-of-binding ELISA has been imple-
mented in laboratories of 6 different countries (Brazil, Italy, 
Nicaragua, Switzerland, United Kingdom, and United States).
Nanotechnology assays have also been developed, including 
simple-to-use readout platforms with data connectivity that use 
disposable microfluidic cartridges for rapid detection of ZIKV 
and DENV antibodies/antigen, and a multiplex serologic assay 
that uses near‐infrared fluorescence enhanced imaging on a 
nanoscale plasmonic gold microarray antigen platform (12-
plex) for antibody detection on 2 different channels [42]. The 
latter was shown to detect and distinguish IgG antibodies from 
ZIKV- and DENV-infected patients, as well as determine the 
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Figure 4. Diagnostic landscape to detect Zika virus (ZIKV) and dengue virus (DENV) infections and the pathway to adoption. The Zika public health emergency triggered 
significant efforts toward the development of new diagnostic assays. Commercial kits and in-house laboratory-developed tests (LDTs) are available to detect ZIKV and DENV 
infections. Multiplex assays that simultaneously detect ZIKV and other arboviral infections (DENV, CHIKV and others) are also available. Target product profiles (TPP) are 
used to define the desired technical and operational characteristics of a test. Quality-assured clinical laboratories can develop, validate, and then implement their in-house 
LDTs. Commercial kits require clinical validation, scale production, distribution, and regulatory approval to be adopted for wide use. Two DENV commercial kits (1 nucleic acid 
amplification test [NAT] and 1 immunoglobulin M [IgM]–capture enzyme-linked immunosorbent assay [ELISA]) have been cleared by the Food and Drug Administration (FDA). 
Emergency use authorization mechanisms by the FDA (the Emergency Use Authorization [EUA] authority) and the World Health Organization (the Emergency Use Assessment 
and Listing [EUAL] procedure) were put into place to accelerate adoption of ZIKV commercial kits in response to the Zika public health emergency. In bold are the types of 
assays that are currently in the pipeline (most assays are stuck at the evaluation stage because of the lack of access to well-characterized clinical specimens). BOB, blockade 
of binding; CDC, Centers for Disease Control and Prevention; IgG, immunoglobulin G; PRNT, plaque-reduction neutralization test; RT-PCR, reverse transcription–polymerase 
chain reaction; R&D, research and development. aAssays that require laboratory infrastructure. bNo rapid diagnostic test (RDT) has been cleared by the FDA nor received 
EUA/EUAL approval to date. 
WHAT IS NEEDED TO MAKE THESE TECHNOLOGIES 
AVAILABLE IN THE FIELD?
For the last 25 years, routine diagnostic approaches have mainly 
included laboratory-based RT-PCR, IgM detection, and PRNT. 
Recognition of Zika as a public health emergency of interna-
tional concern has galvanized the development of new diag-
nostic assays to detect flaviviral infections. While these efforts 
must be encouraged, it is equally important to look down-
stream and identify the issues around translating research into 
a product that is available for use in the field, robust, easy to use, 
reasonably inexpensive, and accurate and has demonstrable 
clinical impact. Previous research and development experience 
has shown that the path from diagnostic development to adop-
tion is long and fragmented [16]. There is a massive loss be-
tween the number of tests that undergo initial development and 
the ones that are taken into adoption for routine use.
HOW CAN WE ACCELERATE TRAVEL ON THE 
PATHWAY FROM DISCOVERY TO ADOPTION?
The 5 major steps identified for optimizing the time to adoption 
(Figure 4A–E) are discussed below and summarized in Table 1.
Market Uncertainty
For diagnostic countermeasures to be readily available, research 
and development must happen before rather than in response 
to an outbreak [43]. The unpredictable and episodic nature 
of outbreaks brings uncertainty to the market, and diagnostic 
companies are left unable to adequately forecast demand and 
establish business models that allow a return on investment. 
Even when a product is brought into the market, there is no 
guarantee that it will be adopted by national health authorities. 
Once a public health emergency of international concern has 
ended, sustained manufacturing support of the product may be 
at stake. Sustainable markets are required to ensure that vali-
dated, approved, high-quality diagnostic tools remain available 
for use in the next outbreak event. As such, innovative financial 
incentives are needed to achieve sustainable emergency prepar-
edness for diagnostic tools. From investments in product devel-
opment to the establishment of partnerships and the creation 
of models to support scalable adoption into national programs, 
a variety of mechanisms have been proposed or established to 
overcome some of the challenges.
The WHO R&D Blueprint for Actions to Prevent Epidemics 
has initiated a call for open-platform technologies to improve 
research and development preparedness against global health 
emergencies, so that in the event of an epidemic diagnostic kits 
can be made available in a short time frame [44]. Furthermore, 
there was a call for a coalition between diagnostic preparedness 
efforts and programs that finance and manage the development 
of vaccines [43]. As a result, CEPI∙dx, a new partnering model 
between the Coalition for Epidemic Preparedness Innovations, 
the Foundation for Innovative New Diagnostics, and other di-
agnostic partners, has been created.
Target Product Profiles (TPPs)
TPPs are used to define the desired minimum technical and oper-
ational characteristics of diagnostic tests, to ensure the develop-
ment of the most-impactful products. TPPs are aspirational in 
nature; however, excessively stringent requirements may deter 
industry partners from developing new products and lead to a 
lack of diagnostic tests meeting those requirements. Strategies 
on how to best define the desired characteristics of TPPs and/or 
inform the use of diagnostic tests when those requirements are 
not met have been proposed. For example, a slightly less accu-
rate test might provide a higher public health impact in terms of 
increased access to testing, compared with a more accurate but 
expensive or complex test (this was the approach used to approve 
the use of HIV self-testing and malaria RDTs in the past). As 
such, it is important to consider how the assay will be used, 
in which setting, and for what purpose (eg, surveillance, early 
warning, or clinical management at the point-of-care), as dif-
ferent applications will have different technical and operational 
Table 1. Summary Table of the Challenges and Drivers Along the Pathway to Adoption
Stepa Challenge(s) Drivers
A Market failure due to uncertainty and lack of demand of public 
health emergencies
Research and development models for diagnostic preparedness, including product 
development; product development partnerships, such as CEPI.dx; other innovative 
financing models
B TPP: the performance characteristics that are set in the TPP 
are aspirational in nature; TPPs are often deemed to be too 
stringent
Risk and benefit models to set accuracy targets may help inform use of diagnostic 
tests when they do not meet the minimum or ideal characteristics set in the TPP
C Lack of clinical samples and resources for clinical validations Development of international reference standard for assay comparability; improved 
access to qualified field laboratory networks; access to proficiency panels; develop-
ment of standardized protocols
D Regulatory approval that is region specific, nontransparent, com-
plex, slow, and costly
Establishment of regulatory networks, common strategies, information sharing, and 
early partnerships
E Limited in-country capacity for wide adoption. Mechanisms for appropriate transfer of technology in a more streamlined fashion; reg-
ulation of quality of local laboratories and in-house assays for national scale-up and 
sustainable implementation
Abbreviation: TPP, target product profile.
aSteps along the pathway to adoption that require optimization (Figure 4A–E).
requirements. A weighted risk and benefits approach within dif-
ferent use scenarios may be more appropriate not only to define 
but also to guide regulatory approval and adoption.
Assay Optimization and Clinical Validation
Internationally accepted reference preparations to compare and 
potentially standardize the different assays are crucially important 
[45]. The WHO has established numerous reference preparations, 
most of them as WHO international standards. For ZIKV RNA, 
the biological standard for molecular tests was characterized for 
the majority of nucleic acid tests available [46], and the complete 
sequence of the ZIKV of this reference preparation was published 
[47] and established as a WHO international standard. Lack of
access to biobanks of well-characterized clinical specimens delays
the process of test optimization, clinical validation, and product
adoption. This lack was identified as the most significant bottle-
neck along the pathway from development to adoption.
Of note, the pathway to adoption of in-house assays and of 
commercial kits differs substantially. Quality-assured clinical 
laboratories can develop, validate, and then implement their 
in-house assays. In contrast, commercial diagnostic kits go 
through regulatory approval processes that may require large 
clinical validation studies, manufacturing under a quality man-
agement system, and some level of distribution capacity. The 
different streams of test development make it challenging to 
determine relative comparability of the accuracy of the differ-
ent tests because very few of them share the same calibration 
controls (ie, internal positive controls used for measuring the 
reactivity of a diagnostic test) or screening panels (ie, a small 
set of coded samples that include high-positive, low-positive, 
cross-reactive, and negative samples, to measure the specificity 
and sensitivity of a diagnostic test). Obtaining irreplaceable 
clinical specimens is costly; the same test materials cannot be 
used throughout the development process. Access to clinical 
samples becomes even more challenging during an outbreak, 
with multiple demands to prioritize assay validation in a short 
time frame and the inability to do head-to-head comparisons.
A coordinated network of quality-assured laboratories with 
staff that are well trained in assay validation and performance 
evaluation could be leveraged a priori. Such an approach would 
alleviate pressure on the countries involved in outbreak response, 
yet provide access to clinical samples and data in a way that may 
be acceptable to the different parties. Of note, local restrictions 
on the export of clinical samples (as witnessed during the ZIKV 
outbreak) limits sample sharing for product validation outside 
the affected countries [43]. The involvement of a network of 
capable local laboratories would have the advantage to over-
come the need for out-of-country sample transfer and facilitate 
country involvement and capacity development at an early stage 
of product development. A transparent and fair process of en-
gagement needs to be put into place to minimize distrust and 
ensure access and equitable sharing of specimens and data. The 
creation of a governance system to provide access to reference 
panels and protocols for test validation has been proposed.
Regulatory Approval
Regulation is essential to ensure the safety, quality, and effec-
tiveness of diagnostic tests, yet >50% of countries do not inde-
pendently regulate in vitro diagnostic tools [48]. The regulatory 
landscape for in vitro diagnostic tools is highly variable, and reg-
ulatory approval mechanisms vary from country to country. This 
makes assay uptake processes slow, costly, and nontransparent. 
Regulatory harmonization between international and national 
regulatory agencies, coupled with coordinated information shar-
ing among the different interest groups (industry, regulators, 
researchers, laboratories, health systems, and patients), is required.
During outbreak events, emergency use authorizations are 
generally used to provide regulatory oversight for diagnostic 
tools that have not previously been evaluated and yet are ur-
gently needed for global response. Both the FDA and the WHO 
have implemented programs (the Emergency Use Authorization 
[EUA] authority and the Emergency Use Assessment and Listing 
[EUAL] procedure, respectively) to address the evaluation of 
new diagnostic tools in an emergency setting. It is important to 
note that in both cases, EUA and/or EUAL approval does not 
extend approval for use outside of an emergency setting. Once 
an emergency has ended, industry will need to seek approval for 
regular use of their products in the intended settings, using ei-
ther FDA 510(k) or WHO prequalification procedures. The data 
obtained during EUA and/or EUAL approval may be included in 
the application package for regular approval; however, it is likely 
that additional data will be required for full approval. In these 
instances, it can be challenging for industry to provide sufficient 
data, as limited access to well-characterized samples can pre-
vent evaluation of the products to the extent required for FDA 
and WHO approval. As of May 2017, several ZIKV diagnostic 
assays have received approval through the EUA (15 assays) and/
or EUAL (2 assays) [45]; however, no single ZIKV assay has been 
cleared by the FDA to date (Figure 4).
Sustainable In-Country Capacity
Sustainable in-country capacity is needed for diagnostic tools to 
respond to the intermediate and long-term infectious diseases 
threats. Higher-cost commercial kits are unlikely to solve this 
issue at a national level in many resource-constrained countries. 
Therefore, key reagents, protocols, and quality control standards 
(eg, proficiency panels) must be made available to national ref-
erence laboratories and other such public-sector entities to en-
sure wide and sustainable adoption.
CONCLUSIONS
Promising technologies for detection of ZIKV and DENV infec-
tions are currently in the pipeline. These technologies have the 
potential to address many of the current challenges of epidemic 
flaviviral diseases. The rate-limiting bottleneck is early access 
to calibration controls and screening panels, as well as access 
to well-characterized samples for development, validation, and 
comparison of the performance of different assays. Proficiency 
testing for both serologic and molecular diagnostic tools should 
be developed for all regions of endemicity, paired with capacity 
building. We suggest that an international reference laboratory re-
sponse for flaviviruses is needed, which would include networks 
of in-country laboratories and preparation of protocols for evalua-
tion studies. This could be achieved through initiatives such as the 
Global Dengue and Aedes Transmitted Disease Consortium, the 
European Virus Archive, the future EVD-LabNet by the European 
Centre for Disease Prevention and Control, or the Zika research 
consortia funded by the European Commission [49]. The know-
ledge obtained should be put into the public domain. Researchers 
and policymakers alike need to ensure mechanisms for greater re-
agent availability and sharing of standard reagents, such as refer-
ence materials, antigens, monoclonal antibodies, cell lines, control 
sera, and standardized protocols. While this workshop focused on 
challenges for arbovirus diagnostic development, the key outcomes 
highlighted here translate to all pathogens of epidemic potential.
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